A year-end update on WM, a distinct entity of lymphoplasmacytic lymphoma presenting with monoclonal pleomorphic immunoglobulin M (IgM) proteins, was recently published in the American Journal of Hematology.
A team of investigators sought to determine if treatment efficacy can be maintained without radiotherapy among patients with newly diagnosed, early-stage, unfavorable Hodgkin lymphoma.
Researchers sought to determine whether R-MegaCHOEP would improve outcomes compared to R-CHOEP-14 in patients with newly diagnosed, aggressive B-cell lymphoma.
The approval was based on data from the single-arm, open-label phase 2 ZUMA-5 study.
A team of investigators sought to assess the safety and efficacy of lenalidomide plus R-CHOP in patients with previously untreated activated B-cell-like subtype of diffuse large B-cell lymphoma.
Investigators assessed outcomes following a radiotherapy dose of 4 Gy in 2 fractions vs 24 Gy in 12 fractions in patients with follicular lymphoma or marginal zone lymphoma.
Investigators will study the pharmacokinetic and pharmacodynamic profile of TG-1701, an irreversible Bruton tyrosine kinase (BTK) inhibitor, in the phase 1 setting.
The ZUMA-5 trial studied whether CAR T cell therapy with axi-cel had any clinical benefits in patients with indolent NHL.
Investigators of a phase 3 trial will compare epcoritamab with investigator’s choice of chemotherapy in patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
The FDA has accepted a supplemental new drug application (sNDA) for brukinsa for the treatment of adults with Waldenström Macroglobulinemia (WM).
The approval was based on data from the open-label, multi-cohort phase 2 UNITY-NHL Trial.
As follicular lymphoma (FL) survival rates have improved, concern that patients are at increased risk for the development of a secondary primary malignancy (SPM) has arisen.
Chimeric antigen receptor (CAR)-T cells can kill off-target tumor cells in the vicinity of the target cells, a phenomenon known as bystander killing. Modulating the expression of the protein mediating this process—Fas—could be a strategy to improve CAR-T efficacy.
The approval was based on data from an open-label phase 1/2 trial in patients aged 1 to 21 years that included 26 patients with relapsed or refractory, systemic ALK-positive ALCL after at least 1 systemic treatment.
Experts discuss clinical, pathologic, and genomic features of Burkitt lymphoma in adults, as well as standard and emerging treatment options for this patient population.
Nearly half of all relapses occurred within the first month of CAR-T infusion.
Peripheral T-cell lymphoma is characterized by extensive epigenetic dysregulation.
Loncastuximab tesirine is an antibody drug conjugate composed of a humanized monoclonal antibody directed against human CD19 and conjugated through a linker to a pyrrolobenzodiazepine dimer cytotoxin.
Investigators summarize current literature surrounding the treatment of NLPHL and discuss treatment considerations for 2 clinical cases.
Researchers report on results with CAR-T therapy in real-world populations of patients with ALL or NHL.
A retrospective analysis highlights the reasons for discontinuation of ibrutinib among patients with mantle cell lymphoma.
Adults treated for Hodgkin lymphoma have an increased risk of death from heart disease, interstitial lung disease, infections, and adverse effects of therapy.
Depending on the type and stage of lymphoma, physicians may choose to avoid having their patients undergo radiation therapy for fear of potential toxic effects in organs.
Small studies, the absence of subtypes, and a historical lack of genetic information has stopped past studies from triggering meaningful public health change, a review asserts.
Exposure to doxorubicin during treatment for DLBCL was linked to a higher risk for cardiovascular diseases, highlighting the need for early cardiac surveillance.
Among patients with early-stage, favorable Hodgkin lymphoma, treatment regimens with conventional chemotherapy may be effective in a subset of patients.
Tazemetostat yielded clinically meaningful, durable responses and was well tolerated in patients with relapsed or refractory follicular lymphoma.
Responses were also observed in patients previously treated with HDAC or mTOR inhibitors.
Combined modality therapy for early-stage favorable HL yielded excellent outcomes and limited excess radiation doses to organs at risk.
The expanded approval was based on data from the randomized, open-label, phase 3 KEYNOTE-204 trial.
Findings suggest that brentuximab vedotin plus nivolumab was well tolerated and active in older patients with previously untreated HL with comorbidities.
A case report detailed reinfection with SARS-CoV-2 in an immunocompromised patient with Waldenström macroglobulinemia.
Pregnant patients with non-Hodgkin lymphoma may be able to receive CHOP-like chemotherapy during pregnancy with some risks.
Although 1 in 1000 lymphoma diagnoses occurs in pregnancy, literature on best practices for treatment in this patient group is limited.
In a phase 2 trial, obinutuzumab added to induction therapy showed promising activity and tolerability for transplant-eligible mantle cell lymphoma.
Investigators characterized the risks of stage- and cause-specific mortality among patients with classical Hodgkin lymphoma treated with chemotherapy.
Among a subset of patients with previously treated Waldenström macroglobulinemia, ibrutinib is highly active and may lead to long-term disease control.
The signaling pathways detected may shed light on new treatment strategies.
Investigators assessed safety and efficacy outcomes of lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma.
In Japan, insurance coverage for breast implantation is limited to procedures using Allergen-manufactured products.
Characterizing gene expression profiles of FL cells from intrafollicular and extrafollicular regions may help to identify future therapeutic targets.
Researchers reviewed the clinical/pathologic aspects of HSTCL and summarized the latest molecular studies and potential novel therapeutic targets.
Delayed evaluation could decrease unnecessary invasive tests.
Using a grading system for skin flare reactions increases potential for continuing administration of mogamulizumab despite the occurrence of this adverse effect.
Investigators measured ixazomib, dexamethasone, and rituximab combination treatment among patients with treatment-naive Waldenström macroglobulinemia.
Researchers assessed diagnosis, risk-stratification, and management of 3 distinct subgroups of primary cutaneous lymphomas.
Novel immunotherapies and small molecule pathway inhibitors are transforming the standard of care for some of the most challenging lymphoma subtypes.
A small study suggests that low-dose pembrolizumab or nivolumab may be effective and safe for the treatment of r/r classical Hodgkin lymphoma.
Neurotoxicity is a common AE associated with CAR-T administration, but there are limited data characterizing it among patients with LBCL who received axi-cel.
Lipid changes in the B-cell lymphoma microenvironment may influence natural killer cell metabolism and function.
In this study, researchers determined that the quantity and quality of discussions regarding survivorship and late effects of treatment between AYA lymphoma survivors and their oncologists is improving, but survivorship information is still lacking.